Trident Limited and Zydus Lifesciences Limited have both announced board meetings scheduled for Monday, February 9, 2026, to review and approve their respective Q3FY26 unaudited financial results. Both companies will focus on financial statements covering the quarter and nine months ended December 31, 2025, encompassing standalone and consolidated results. The announcements were made in compliance with SEBI (LODR) Regulations, 2015, with Trident issuing its notification on January 28, 2026, and Zydus on January 27, 2026.
Both board meetings are scheduled for Monday, February 9, 2026, with the primary purpose of reviewing Q3FY26 unaudited financial results. The results will cover the quarter and nine months ended December 31, 2025, representing the third quarter of fiscal year 2026. Trident Limited's meeting will encompass both standalone and consolidated financial statements, while Zydus Lifesciences will focus on consideration and approval of unaudited financial results. The announcements were made in accordance with SEBI Regulation 29(1) and other applicable provisions, ensuring proper regulatory compliance.
Both companies have implemented trading window restrictions in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. Trident Limited has specified that the trading window will reopen at 9:00 AM IST on Thursday, February 12, 2026, aligning with the company's Code of Conduct for Regulating, Monitoring and Reporting of Trades by Designated Persons. Zydus Lifesciences has implemented similar restrictions, with the trading window remaining closed until Wednesday, February 11, 2026, and normal trading activities resuming on Thursday, February 12, 2026 for all Directors and Designated Persons.
Both companies have ensured proper regulatory compliance through formal notifications to major stock exchanges. The announcements were communicated to the National Stock Exchange of India Limited and BSE Limited where both companies are listed. Trident Limited's formal communication was signed by Sushil Sharma, Company Secretary with ICSI Membership No. F6535, while Zydus Lifesciences' notice was signed by Dhaval N. Soni, Company Secretary and Compliance Officer with Membership No. FCS7063. Zydus Lifesciences trades under BSE code 532321 and NSE code Zyduslife, maintaining transparency in corporate communications with appropriate authentication guidelines for stakeholders.
